TNF and Bjornstad syndrome: As shown in Table 1, the Ke0 value of TNF-α for PTD was 3.4 × 10−4, suggesting a moderate delay in modulating TNF-α, implicating TNF-α as a primary target for PTD’s anti-rheumatoid arthritis effects in vivo.